KeyCorp director granted 7,352 deferred shares
Gile Elizabeth R. reported acquisition or exercise transactions in this Form 4 filing.
Rhea-AI Filing Summary
Gile Elizabeth R. reported acquisition or exercise transactions in this Form 4 filing.
KEYCORP director Elizabeth R. Gile received 7,352 Deferred Shares as a compensation award. Each Deferred Share is the economic equivalent of one Common Share and was granted under KeyCorp's Amended and Restated Directors' Deferred Share Sub-Plan of the KeyCorp 2026 Equity Compensation Plan.
Payment of these Deferred Shares has been deferred until October 1, 2029. Following this award, Gile now holds 132,059 Deferred Shares, including approximately 1,338 dividend-equivalent Deferred Shares accrued in March 2026, and 45,201 Common Shares directly. This is a routine, non-cash equity compensation transaction rather than an open-market trade.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Deferred Shares | 7,352 | $0.00 | $0.00 |
| holding | Common Shares | -- | -- | -- |
Footnotes (4)
- F1. Each Deferred Share is the economic equivalent of one Common Share.
- F2. Under the terms of KeyCorp's Amended and Restated Directors' Deferred Share Sub-Plan of the KeyCorp 2026 Equity Compensation Plan (the "Deferred Share Plan"), payment of the deferred shares has been deferred until October 1, 2029.
- F3. The Deferred Shares were awarded under the Deferred Share Plan.
- F4. Includes approximately 1,338 dividend-equivalent Deferred Shares accrued in March 2026.
Key Figures
Key Terms
KeyCorp 2026 Equity Compensation Plan financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did KEY (KeyCorp) director Elizabeth R. Gile report in this Form 4?
AI-generated analysis. How Rhea-AI works. Not financial advice.